PF-04620110 is primarily researched for its potential in treating metabolic disorders, particularly type 2 diabetes. It functions as a diacylglycerol acyltransferase 1 (DGAT1) inhibitor, which plays a crucial role in triglyceride synthesis. By inhibiting DGAT1, it reduces the absorption of dietary fats, leading to improved insulin sensitivity and glucose metabolism. This makes it a promising candidate for managing obesity-related diabetes. Additionally, its application is being explored in addressing non-alcoholic fatty liver disease (NAFLD) due to its ability to modulate lipid metabolism. Ongoing studies aim to evaluate its efficacy and safety in clinical settings for these conditions.